Freenome Raises $254 Million Down Round
Freenome, a Prime Unicorn Index component once valued at $2.6 billion, recently raised a $254 million Series F down round. Freenome is a biotechnology company specializing in developing blood tests for early cancer detection. Using artificial intelligence and advanced genomics, Freenome aims to identify cancerous cells in the bloodstream early,